Cat. No. 2238
Chemical Name: 1,3-Dihydro-3-[(1-methyl-1H-indol-3
Biological ActivityPotent, selective inhibitor of the NGF receptor tyrosine kinase A (TrkA) (IC50 = 2 nM). Displays > 100-fold selectivity over a range of other kinases.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Wood et al (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg.Med.Chem.Lett. 14 953. PMID: 15013000.
If you know of a relevant reference for GW 441756 please let us know.
Citations are publications that use Tocris products. Selected citations for GW 441756 include:
Rees et al (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Oncotarget 12 109. PMID: 26656090.
Lawn et al (2015) Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. Nat Chem Biol 290 3814. PMID: 25538243.
Edwards et al (2011) Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 103 1162. PMID: 21771732.
Do you know of a great paper that uses GW 441756 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GW 441756, supplier, Potent, selective, TrkA, inhibitors, inhibits, Neurotrophin, Receptors, Receptor, Tyrosine, Kinases, RTKs, GW441756, GlaxoSmithKline, GSK, Tocris Bioscience, Trk Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
June 14 - 17, 2017
Boston, MA, USA